Spinal vaccine trial targets breast cancer in the brain
NCT ID NCT05809752
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This early-phase study tests a new dendritic cell vaccine given directly into the spinal fluid for people with triple-negative or HER2-positive breast cancer that has spread to the lining of the brain (leptomeningeal disease). The main goal is to find the highest safe dose. About 15 participants will be enrolled. The vaccine is designed to train the immune system to attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.